116 related articles for article (PubMed ID: 22730602)
1. Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy.
Hoppe BS; Flampouri S; Lynch J; Slayton W; Zaiden R; Li Z; Mendenhall NP
Oncology (Williston Park); 2012 May; 26(5):456-9, 462-5. PubMed ID: 22730602
[TBL] [Abstract][Full Text] [Related]
2. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
3. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
6. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma.
Jørgensen AY; Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Rosenschöld PM; Petersen PM; Specht L
Acta Oncol; 2013 Oct; 52(7):1559-65. PubMed ID: 24047340
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients.
Andolino DL; Hoene T; Xiao L; Buchsbaum J; Chang AL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e667-71. PubMed ID: 21459527
[TBL] [Abstract][Full Text] [Related]
8. Proton therapy in the management of lymphoma.
Ho CK; Flampouri S; Hoppe BS
Cancer J; 2014; 20(6):387-92. PubMed ID: 25415683
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
[TBL] [Abstract][Full Text] [Related]
10. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study.
Nichols RC; Huh SN; Henderson RH; Mendenhall NP; Flampouri S; Li Z; D'Agostino HJ; Cury JD; Pham DC; Hoppe BS
Clin Lung Cancer; 2011 Jul; 12(4):252-7. PubMed ID: 21726825
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas.
Boehling NS; Grosshans DR; Bluett JB; Palmer MT; Song X; Amos RA; Sahoo N; Meyer JJ; Mahajan A; Woo SY
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):643-52. PubMed ID: 21277111
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiation therapy, protons, and the risk of second cancers.
Hall EJ
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):1-7. PubMed ID: 16618572
[TBL] [Abstract][Full Text] [Related]
13. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma.
Filippi AR; Ciammella P; Piva C; Ragona R; Botto B; Gavarotti P; Merli F; Vitolo U; Iotti C; Ricardi U
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):370-5. PubMed ID: 24613810
[TBL] [Abstract][Full Text] [Related]
14. [Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: experience of the Gustave-Roussy Institute].
Paumier A; Khodari W; Beaudre A; Ghalibafian M; Blanchard P; Al Hamokles H; Bhari M; Lessard N; Girinsky T
Cancer Radiother; 2011 Dec; 15(8):709-15. PubMed ID: 22116023
[TBL] [Abstract][Full Text] [Related]
15. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?
Girinsky T; Pichenot C; Beaudre A; Ghalibafian M; Lefkopoulos D
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):218-26. PubMed ID: 16169675
[TBL] [Abstract][Full Text] [Related]
16. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy.
Cotter SE; Herrup DA; Friedmann A; Macdonald SM; Pieretti RV; Robinson G; Adams J; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1367-73. PubMed ID: 20934266
[TBL] [Abstract][Full Text] [Related]
17. Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison.
Kandula S; Zhu X; Garden AS; Gillin M; Rosenthal DI; Ang KK; Mohan R; Amin MV; Garcia JA; Wu R; Sahoo N; Frank SJ
Med Dosim; 2013; 38(4):390-4. PubMed ID: 23916884
[TBL] [Abstract][Full Text] [Related]
18. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.
Palm A; Johansson KA
Acta Oncol; 2007; 46(4):462-73. PubMed ID: 17497313
[TBL] [Abstract][Full Text] [Related]
19. Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity.
Hodgson DC; Hudson MM; Constine LS
Semin Radiat Oncol; 2007 Jul; 17(3):230-42. PubMed ID: 17591570
[TBL] [Abstract][Full Text] [Related]
20. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
